Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Diabetes Metab J. 2022 Jan;46(1):71-80. doi: 10.4093/dmj.2020.0274. Epub 2021 Jun 16.
To compare the efficacy and safety of two insulin self-titration algorithms, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) and EDITION, for insulin glargine 300 units/mL (Gla-300) in Korean individuals with uncontrolled type 2 diabetes mellitus (T2DM).
In a 12-week, randomized, open-label trial, individuals with uncontrolled T2DM requiring basal insulin were randomized to either the INSIGHT (adjusted by 1 unit/day) or EDITION (adjusted by 3 units/week) algorithm to achieve a fasting self-monitoring of blood glucose (SMBG) in the range of 4.4 to 5.6 mmol/L. The primary outcome was the proportion of individuals achieving a fasting SMBG ≤5.6 mmol/L without noct urnal hypoglycemia at week 12.
Of 129 individuals (age, 64.1±9.5 years; 66 [51.2%] women), 65 and 64 were randomized to the INSIGHT and EDITION algorithms, respectively. The primary outcome of achievement was comparable between the two groups (24.6% vs. 23.4%, P=0.876). Compared with the EDITION group, the INSIGHT group had a greater reduction in 7-point SMBG but a similar decrease in fasting plasma glucose and glycosylated hemoglobin. The increment of total daily insulin dose was significantly higher in the INSIGHT group than in the EDITION group (between-group difference: 5.8±2.7 units/day, P=0.033). However, body weight was significantly increased only in the EDITION group (0.6±2.4 kg, P=0.038). There was no difference in the occurrence of hypoglycemia between the two groups. Patient satisfaction was significantly increased in the INSIGHT group (P=0.014).
The self-titration of Gla-300 using the INSIGHT algorithm was effective and safe compared with that using the EDITION algorithm in Korean individuals with uncontrolled T2DM (ClinicalTrials.gov number: NCT03406663).
本研究旨在比较两种胰岛素自我滴定算法(INSIGHT 和 EDITION)在韩国未经控制的 2 型糖尿病(T2DM)患者中使用甘精胰岛素 300 单位/毫升(Gla-300)的疗效和安全性。
在一项为期 12 周、随机、开放标签试验中,需要基础胰岛素治疗的未经控制的 T2DM 患者被随机分配至 INSIGHT (每天调整 1 单位)或 EDITION (每周调整 3 单位)算法,以实现空腹自我监测血糖(SMBG)在 4.4 至 5.6mmol/L 的范围内。主要结局是在第 12 周时达到空腹 SMBG≤5.6mmol/L 且无夜间低血糖的患者比例。
在 129 名患者(年龄 64.1±9.5 岁;66 [51.2%] 名女性)中,分别有 65 名和 64 名患者被随机分配至 INSIGHT 和 EDITION 组。两组之间的主要结局(达到率)相似(24.6% vs. 23.4%,P=0.876)。与 EDITION 组相比,INSIGHT 组的 7 点 SMBG 降低更明显,但空腹血浆葡萄糖和糖化血红蛋白的降低相似。INSIGHT 组的总日胰岛素剂量增加显著高于 EDITION 组(组间差异:5.8±2.7 单位/天,P=0.033)。然而,只有 EDITION 组的体重显著增加(0.6±2.4kg,P=0.038)。两组之间低血糖的发生没有差异。INSIGHT 组患者满意度显著增加(P=0.014)。
与 EDITION 算法相比,在韩国未经控制的 T2DM 患者中,使用 INSIGHT 算法滴定 Gla-300 是有效且安全的(ClinicalTrials.gov 编号:NCT03406663)。